Improving the Care and Treatment of Monkeypox Patients in Low-Resource Settings: Applying Evidence from Contemporary Biomedical and Smallpox Biodefense Research
- PMID: 29231870
- PMCID: PMC5744154
- DOI: 10.3390/v9120380
Improving the Care and Treatment of Monkeypox Patients in Low-Resource Settings: Applying Evidence from Contemporary Biomedical and Smallpox Biodefense Research
Abstract
Monkeypox is a smallpox-like illness that can be accompanied by a range of significant medical complications. To date there are no standard or optimized guidelines for the clinical management of monkeypox (MPX) patients, particularly in low-resource settings. Consequently, patients can experience protracted illness and poor outcomes. Improving care necessitates developing a better understanding of the range of clinical manifestations-including complications and sequelae-as well as of features of illness that may be predictive of illness severity and poor outcomes. Experimental and natural infection of non-human primates with monkeypox virus can inform the approach to improving patient care, and may suggest options for pharmaceutical intervention. These studies have traditionally been performed to address the threat of smallpox bioterrorism and were designed with the intent of using MPX as a disease surrogate for smallpox. In many cases this necessitated employing high-dose, inhalational or intravenous challenge to recapitulate the severe manifestations of illness seen with smallpox. Overall, these data-and data from biomedical research involving burns, superficial wounds, herpes, eczema vaccinatum, and so forth-suggest that MPX patients could benefit from clinical support to mitigate the consequences of compromised skin and mucosa. This should include prevention and treatment of secondary bacterial infections (and other complications), ensuring adequate hydration and nutrition, and protecting vulnerable anatomical locations such as the eyes and genitals. A standard of care that considers these factors should be developed and assessed in different settings, using clinical metrics specific for MPX alongside consideration of antiviral therapies.
Keywords: Orthopoxvirus; animal model; clinical syndrome; monkeypox; standard of care.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5744154/bin/viruses-09-00380-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5744154/bin/viruses-09-00380-g002.gif)
Similar articles
-
A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak.Viruses. 2022 Aug 25;14(9):1870. doi: 10.3390/v14091870. Viruses. 2022. PMID: 36146675 Free PMC article. Review.
-
Human monkeypox infection threat: A comprehensive overview.PLoS Negl Trop Dis. 2023 Apr 20;17(4):e0011246. doi: 10.1371/journal.pntd.0011246. eCollection 2023 Apr. PLoS Negl Trop Dis. 2023. PMID: 37079486 Free PMC article. Review.
-
[Monkeypox].Rev Med Liege. 2022 Jul;77(7-8):452-455. Rev Med Liege. 2022. PMID: 35924502 French.
-
Diagnosis and Management of Monkeypox: A Review for the Emergency Clinician.Ann Emerg Med. 2023 Jan;81(1):20-30. doi: 10.1016/j.annemergmed.2022.07.014. Epub 2022 Sep 15. Ann Emerg Med. 2023. PMID: 36117012 Free PMC article. Review.
-
Rapid Amplicon Nanopore Sequencing (RANS) for the Differential Diagnosis of Monkeypox Virus and Other Vesicle-Forming Pathogens.Viruses. 2022 Aug 18;14(8):1817. doi: 10.3390/v14081817. Viruses. 2022. PMID: 36016439 Free PMC article.
Cited by
-
Poxviridae Pneumonia.Adv Exp Med Biol. 2024;1451:183-204. doi: 10.1007/978-3-031-57165-7_12. Adv Exp Med Biol. 2024. PMID: 38801579 Review.
-
Monkeypox: From Emerging Trends to Therapeutic Concerns.Cureus. 2024 Apr 23;16(4):e58866. doi: 10.7759/cureus.58866. eCollection 2024 Apr. Cureus. 2024. PMID: 38800170 Free PMC article. Review.
-
Knowledge about, attitudes toward and acceptance and predictors of intention to receive the mpox vaccine among cancer patients in China: A cross-sectional survey.Hum Vaccin Immunother. 2024 Dec 31;20(1):2337157. doi: 10.1080/21645515.2024.2337157. Epub 2024 Apr 21. Hum Vaccin Immunother. 2024. PMID: 38644633 Free PMC article.
-
Role of vaccination in patients with human monkeypox virus and its cardiovascular manifestations.Ann Med Surg (Lond). 2024 Jan 4;86(3):1506-1516. doi: 10.1097/MS9.0000000000001674. eCollection 2024 Mar. Ann Med Surg (Lond). 2024. PMID: 38463133 Free PMC article. Review.
-
Global research profile on monkeypox-related literature (1962-2022): A bibliometric analysis.Narra J. 2022 Dec;2(3):e96. doi: 10.52225/narra.v2i3.96. Epub 2022 Dec 14. Narra J. 2022. PMID: 38449907 Free PMC article.
References
-
- Khodakevich L., Szczeniowski M., Nambu M.D., Jezek Z., Marennikova S., Nakano J., Meier F. Monkeypox virus in relation to the ecological features surrounding human settlements in Bumba zone, Zaire. Trop. Geogr. Med. 1987;39:56–63. - PubMed
-
- McCollum A.M., Nakazawa Y., Ndongala G.M., Pukuta E., Karhemere S., Lushima R.S., llunga B.K., Kabamba J., Wikins K., Gao J., et al. Human Monkeypox in the Kivus, a Conflict Region of the Democratic Republic of the Congo. Am. J. Trop. Med. Hyg. 2015;93:718–721. doi: 10.4269/ajtmh.15-0095. - DOI - PMC - PubMed
-
- Rimoin A.W., Mulembakani P.M., Johnston S.C., Lloyd Smith J.O., Kisalu N.K., Kinkela T.L., Blumberg S., Thomassen H.A., Pike B.L., Fair J.N., et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc. Natl. Acad. Sci. USA. 2010;107:16262–16267. doi: 10.1073/pnas.1005769107. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical